TrialPanorama/TrialPanorama-database huggingface dataset:
Primary endpoint: pain on the day of surgery
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain during mobilization on the first 2 postoperative days
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum levels of ubiquinone-10
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: serum levels of alpha- and gamma-tocopherol
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Bioequivalence of levosulpiride formulations
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Frequency of LOH on 17p13.1 correlated to metastatic HCC recurrence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Frequency of LOH on 4q and 8p associated with progression of HCC
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: Delayed latency of wave I
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Amplitudes of DPOAE at 8 kHz
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Amplitudes of DPOAE at 6 kHz
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Change in C-reactive protein at 12 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: ongoing pregnancy rate per stimulated cycle
Endpoint domain: Physiological/clinical
Endpoint subdomain: Reproductive system and breast outcomes
Primary endpoint: Maximal itch intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parasitaemia reduction rate at H24
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Markers of bone metabolism
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Reduction loss
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Excellent and good rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Overall toxicity rate
Endpoint domain: Adverse events/effects
Primary endpoint: Temporal lobe necrosis rate
Endpoint domain: Adverse events/effects
Primary endpoint: Deafness rate
Endpoint domain: Adverse events/effects
Primary endpoint: Linkage to care within 6 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Initiation of ART within 3 months
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: percentage of the predicted heart rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: percentage of the predicted resting energy expenditure
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: lean body mass accretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Area of ecchymosis
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rank order of ecchymosis severity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Ease of recovery per patient report
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: symptom scores (rhinitis and asthma)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Side-effects
Endpoint domain: Adverse events/effects
Primary endpoint: Treatment tolerance
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Prevalence of handgun carrying
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EPC numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: EMP numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: PMP numbers
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Knowledge scores of students
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Performance scores of students
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Composite outcome of death or nonfatal myocardial infarction
Endpoint domain: Mortality/survival
Primary endpoint: Clinically important hypotension
Endpoint domain: Adverse events/effects
Primary endpoint: Nonfatal cardiac arrest
Endpoint domain: Adverse events/effects
Primary endpoint: Medication adherence (MA)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cholesterol absorption response to ezetimibe
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: VDR expression
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Postoperative blood loss and transfusion requirements
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: urinary biomarker score for rapidly progressive disease
Endpoint domain: Physiological/clinical
Endpoint subdomain: Renal and urinary outcomes
Primary endpoint: levels of adiponectin
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: leptin:adiponectin ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: tissue oxygen saturation
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: capillary blood flow
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: postcapillary venous filling pressure
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Urinary 11‐dehydro‐thromboxane B2 excretion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Menstrual wellbeing outcomes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Psychophysical wellbeing outcomes
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: speech perception in complex noise conditions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Peak PR3-ANCA values
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Median time to reach peak values
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: median time to clinically evident functional decline
Endpoint domain: Mortality/survival
Primary endpoint: probability of remaining with no clinically evident functional loss
Endpoint domain: Mortality/survival
Primary endpoint: progress in health
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: rate of wound infection
Endpoint domain: Adverse events/effects
Primary endpoint: cardiac mortality at 5 years
Endpoint domain: Mortality/survival
Primary endpoint: Proportion of participants estimating within 20% of weighed grams of food consumed
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mRNA expression of AR, ERα and aromatase
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: decline in ADL functioning
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: use of supportive assistance
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: return to independent preoperative living situation
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: goblet cell density on the superior conjunctiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: cell‐to‐cell contact of epithelial cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: keratinization on the temporal conjunctiva
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Cord plasma glucose levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Cerebral hypoperfusion
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Time until return of normal sensory and motor functions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Time until first opioid request
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Total oral morphine equivalents administered
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Change in AF burden
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in serum IgE
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Reduction in C-C motif chemokine ligand 17
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Transit time through the gastrointestinal tract
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean akinesia scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Chemosis occurrence
Endpoint domain: Adverse events/effects
Primary endpoint: Healing of gastric ulcers
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: HAM-A total score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: HAM-A psychic anxiety factor score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CGI scale score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Clinical duration of action
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Positive diagnostic rate
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neoplasms and related outcomes
Primary endpoint: absolute CO2 reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: relative CO2 reactivity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Number of high-quality CPR compressions
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pain amelioration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: methadone dose
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Intensity of pain experienced during application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Discomfort during application
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: symptomatic remission rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Self-reported adherence to diabetic diet and exercise
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Serum cholesterol reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Smoking cessation rates
Endpoint domain: Life impact
Endpoint subdomain: Personal circumstances
Primary endpoint: peak torque in extensor muscle strength
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Mean increase of 25-hydroxyvitamin D levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reduction in the proportion of interleukin-17(+)CD4(+) T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Decrease in the proportion of effector memory CD4(+) T cells
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Quality of the intervention
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Performance of the nurse
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Increase in chlamydia testing rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: mean HbA(1c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean FPG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: mean PPG
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: incidence of shunt failure
Endpoint domain: Adverse events/effects
Primary endpoint: Preference for hospital as healthcare facility for chest pain
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Total steps per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: BOUT-MVPA steps per day
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Fear scores
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Changes in COx after vasoactive drug administration
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: ScO2 response to pressure changes
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: serum lipid profiles
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: COPD-related hospitalizations and ED visits per patient
Endpoint domain: Resource use
Endpoint subdomain: Hospital
Primary endpoint: Pit and fissure stain shade lightening
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Parent vaccination attitudes
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Vaccine hesitancy
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: overall improvement rates
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: High Density Lipoprotein-cholesterol (HDL-c)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Average primary resistances
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Parenting behaviour in conflict situations
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Depression and anxiety scores of parents
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Metabolic control (A1c levels)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: organisation of palliative care
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: professional collaboration
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: CVAS decrease
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LCQ scores improvement
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: suppression of eosinophilic inflammation
Endpoint domain: Physiological/clinical
Endpoint subdomain: Immune system outcomes
Primary endpoint: Dyspnea improvement
Endpoint domain: Life impact
Endpoint subdomain: Emotional functioning/wellbeing
Primary endpoint: Neurologic recovery
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: dryness/keratitis score improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Prevalence of childhood obesity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Time to Hospital Stay (THS)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Irrigant absorbed
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: International Prostate Symptoms Scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Maximum urinary flow rates
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Emotional valence effects
Endpoint domain: Physiological/clinical
Endpoint subdomain: Nervous system outcomes
Primary endpoint: Mean total percentage of time with pH <4
Endpoint domain: Physiological/clinical
Endpoint subdomain: Gastrointestinal outcomes
Primary endpoint: Mean total GERD-HRQL score improvement
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status
Primary endpoint: Complete discontinuation of PPIs
Endpoint domain: Resource use
Endpoint subdomain: Need for further intervention
Primary endpoint: Gross motor development at 15 months CA
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Independent walking
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Repeat pregnancy at 6 months postpartum
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: STI incidence
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Survival after local recurrence
Endpoint domain: Mortality/survival
Primary endpoint: Referral of partners for HIV-1 testing
Endpoint domain: Physiological/clinical
Endpoint subdomain: Infections and infestations outcomes
Primary endpoint: Visceral fat area reduction
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Increase in serum free fatty acids
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Increase in acylcarnitine levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: Metabolic and nutritional outcomes
Primary endpoint: Composite end points of cardiovascular death, nonfatal MI, and stroke
Endpoint domain: Mortality/survival
Primary endpoint: Need for GPIIb/IIIa inhibitors
Endpoint domain: Resource use
Primary endpoint: Reduction of pruritus score
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: pulse wave velocity
Endpoint domain: Physiological/clinical
Endpoint subdomain: Vascular outcomes
Primary endpoint: Decrease in antacid use
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of publication of randomized trials
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Reduction of symptoms on the malaise scale
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Reaching EDSS score ≥6.0
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: weight loss after 1 year
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: LVM index (LVMI)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Cardiovascular outcomes
Primary endpoint: Proportion of participants increasing medication use or dose intensity
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: leg oedema incidence
Endpoint domain: Adverse events/effects
Primary endpoint: obesity-related cancer cases
Endpoint domain: Mortality/survival
Primary endpoint: Severity of dysmenorrheal pain
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Systemic symptoms of dysmenorrhea
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Quality of Recovery (QoR) scores
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: Discharge time
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: Epidermal hydration
Endpoint domain: Physiological/clinical
Endpoint subdomain: Skin and subcutaneous tissue outcomes
Primary endpoint: Serum IgE levels
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Rate of troublesome side-effects
Endpoint domain: Adverse events/effects
Primary endpoint: Efficacy of prostatic artery embolisation (PAE)
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: CDI recurrence prevention
Endpoint domain: Mortality/survival
Primary endpoint: Decrease in wound defect area
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Decrease in wound defect depth
Endpoint domain: Physiological/clinical
Endpoint subdomain: Surgical and medical procedures outcomes
Primary endpoint: Intensification of local microhemodynamics
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Probability of peak-stimulated LH suppression
Endpoint domain: Physiological/clinical
Endpoint subdomain: Endocrine outcomes
Primary endpoint: Knee Scores Improvement
Endpoint domain: Physiological/clinical
Endpoint subdomain: Musculoskeletal and connective tissue outcomes
Primary endpoint: Over-the-counter sales of antibiotics
Endpoint domain: Resource use
Endpoint subdomain: Other resource use
Primary endpoint: mean global score
Endpoint domain: Life impact
Endpoint subdomain: Global quality of life
Primary endpoint: verbal memory performance
Endpoint domain: Life impact
Endpoint subdomain: Cognitive functioning
Primary endpoint: Nasal Airway Resistance (NAR)
Endpoint domain: Physiological/clinical
Endpoint subdomain: Respiratory outcomes
Primary endpoint: Total plasma volume
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Hematocrit ratio
Endpoint domain: Physiological/clinical
Endpoint subdomain: Blood and lymphatic system outcomes
Primary endpoint: Brief Fatigue Inventory scores
Endpoint domain: Life impact
Endpoint subdomain: Fatigue
Primary endpoint: MENQOL physical domain scores
Endpoint domain: Life impact
Endpoint subdomain: Physical functioning
Primary endpoint: Median hot flashes for 24 hours
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Social function impairment
Endpoint domain: Life impact
Endpoint subdomain: Social functioning
Primary endpoint: Chinese medical syndrome efficacy
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: craving for cannabis
Endpoint domain: Life impact
Endpoint subdomain: null
Primary endpoint: incidence of all stroke
Endpoint domain: Physiological/clinical
Endpoint subdomain: Neurological outcomes
Primary endpoint: responses to A‐tDCS in language measures
Endpoint domain: Physiological/clinical
Endpoint subdomain: General outcomes
Primary endpoint: Mental Health (MH) scores
Endpoint domain: Life impact
Endpoint subdomain: Perceived health status